Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (4467)	6/5/1998 10:26:00 AM
From: Craig Markell	Read Replies (2) \| Respond to of 7041

I'm a bit puzzled by the reaction to the various articles (and reaction) on the Vasomax results. The recent article posted by Linda states: --- "The test results revealed Tuesday at the American Urological Association meeting in San Diego showed that while Zonagen's impotence pill Vasomax works and is safe, it was less effective than Viagra." --- Isn't this old news? We already knew that Viagra has a 70% success rate and that Vasomax would be considerably lower. If we're talking about a billion dollar market, what's wrong with a small chunk of it. Obviously Viagra will be the first line of attack, it's the other 30% of the market that Vasomax is going after. I was also told that a person on Viagra could build up a resistance to it after some period of time (anyone have info on this regarding either drug?). Vasomax could get this piece of the market as well. Thanks, Craig